These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 25773177)

  • 1. PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation.
    Gao Q; Jia Y; Yang G; Zhang X; Boddu PC; Petersen B; Narsingam S; Zhu YJ; Thimmapaya B; Kanwar YS; Reddy JK
    Am J Pathol; 2015 May; 185(5):1396-408. PubMed ID: 25773177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice.
    Huang J; Jia Y; Fu T; Viswakarma N; Bai L; Rao MS; Zhu Y; Borensztajn J; Reddy JK
    FASEB J; 2012 Feb; 26(2):628-38. PubMed ID: 22009939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
    Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
    J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation.
    Wu X; Zheng H; Yang R; Luan X; Zhang L; Jin Q; Jin Y; Xue J
    Am J Physiol Endocrinol Metab; 2019 Sep; 317(3):E436-E445. PubMed ID: 31211621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
    Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
    Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.
    Zhang H; Shen WJ; Cortez Y; Kraemer FB; Azhar S
    Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(1):G72-86. PubMed ID: 23104557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
    Ide T; Tsunoda M; Mochizuki T; Murakami K
    Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice.
    Barbosa-da-Silva S; Souza-Mello V; Magliano DC; Marinho Tde S; Aguila MB; Mandarim-de-Lacerda CA
    Life Sci; 2015 Apr; 127():73-81. PubMed ID: 25748419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
    Park HS; Hur HJ; Kim SH; Park SJ; Hong MJ; Sung MJ; Kwon DY; Kim MS
    Mol Nutr Food Res; 2016 Sep; 60(9):1944-55. PubMed ID: 27145114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
    Ahmad A; Ali T; Kim MW; Khan A; Jo MH; Rehman SU; Khan MS; Abid NB; Khan M; Ullah R; Jo MG; Kim MO
    Metabolism; 2019 Jan; 90():31-43. PubMed ID: 30473057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting.
    Hashimoto T; Cook WS; Qi C; Yeldandi AV; Reddy JK; Rao MS
    J Biol Chem; 2000 Sep; 275(37):28918-28. PubMed ID: 10844002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway.
    Liao J; Xie X; Wang N; Wang Y; Zhao J; Chen F; Qu F; Wen W; Miao J; Cui H
    Phytomedicine; 2024 Feb; 124():155285. PubMed ID: 38185065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
    Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
    Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor α.
    Chen X; Zhang F; Gong Q; Cui A; Zhuo S; Hu Z; Han Y; Gao J; Sun Y; Liu Z; Yang Z; Le Y; Gao X; Dong LQ; Gao X; Li Y
    Diabetes; 2016 Jul; 65(7):1904-15. PubMed ID: 27207533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.